Wearable sensor data combined with machine learning predicts fall risk in Parkinson's patients, enhancing preventive care and ...
There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong ...
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...
Bobbi Conner talks with MUSC's Dr. Vanessa Hinson about what causes Parkinson’s disease and what can be done to reduce the ...
the main treatment for Parkinson's disease. Therefore, the exploration of new biomarkers is essential to accurately stratify patients, especially in the early stages, when the diagnosis is more ...
A new study from the University of Oxford demonstrates how clinicians could use data to predict the risk of falls in people ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...
AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback